Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of **Hyaluronic Acid (HA)** and **Platelet-Rich Plasma (PRP)**, which is being evaluated for the treatment of knee osteoarthritis. Hyaluronic acid acts as a viscosupplement, providing mechanical lubrication and shock absorption within the joint to compensate for the loss of synovial fluid quality. Platelet-Rich Plasma is an autologous blood product containing a high concentration of platelets that, upon activation, release various growth factors (such as TGF-β, PDGF, and VEGF) and cytokines. These factors promote tissue repair, stimulate chondrocyte proliferation, and modulate the inflammatory environment of the joint. The combination is hypothesized to have a synergistic effect, where HA improves the joint's physical environment while PRP stimulates biological regenerative processes. A specific study by the **University of Karachi** (NCT04133103) has investigated this combination in patients with Grade II-III knee osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + platelet rich plasma.